-+ 0.00%
-+ 0.00%
-+ 0.00%

IN8Bio Presented Results From The Fully Enrolled Phase 1 Trial Of INB-200 At The Annual Meeting Society For Neuro-oncology

Benzinga·11/25/2024 12:08:15
Listen to the news
  • 50% of patients who received repeated doses (n=10) remained alive and in remission beyond the expected median overall survival (OS) from standard-of-care Stupp regimen while none of the patients who received a single dose (n=3) achieved this outcome.
  • Biopsy results confirmed the presence and persistence of gamma-delta T cells along with CD3+ and CD8+ T cells within the brain tumor microenvironment in two patients following treatment with INB-200.
  • Patients in the multi-dose cohorts demonstrated a trend toward improved peripheral T cell recovery, suggesting potential immune system benefits.
  • The majority of patients exceeded their expected progression free survival (PFS) based on age and tumor status; five patients remain alive and three patients have returned to their occupations, with one patient remaining progression free at 40.5 months post treatment.